Margins Inflect, but FY28 Story Trades at Execution Discount
H1 delivered ahead of guidance with strong margin expansion, but the FY28 inflection thesis (new facilities, Prathyak R&D) remains unmonetized. Institutions are trimming; the 34% drawdown reflects caution on capex returns, not fundamental deterioration.
Buy
Confidence 8/10
₹10.5 Cr
+32.7% QoQ
47.5%
+660 bps QoQ
₹376 Cr
50% of ₹750 Cr, on track
The gap: strong quarter, unproven catalyst
On the surface, Q2 looked clean — 9.1% revenue growth, PAT up 32.7%, gross margin up 660 basis points, and H1 EBITDA margin at 17.6% already beating the full-year 17% guidance. But the stock has fallen 33.76% from its all-time high of ₹705, trading below its 20-day and 50-day moving averages. More telling: institutions are trimming. FII ownership fell 170 basis points QoQ to 4.03%; DII fell 433 basis points to 8.53%. The disconnect is not the reported quarter; it's what happens next. Management promises an "inflection" in FY28 — three new profit centers (Unit III, Adelaide, Prathyak R&D) coming online by Q4 FY27 and Q1 FY28. But none are monetizing yet. That's where the market is placing its doubt.
What the quarter actually delivered
Gross margin is the engine. At 47.5%, it's up 660 basis points from 40.9% in Q1. Management's claim: raw material costs fell 3% despite 9% revenue growth, driven by inventory management (clearing high-cost prior-quarter stock). The math checks — this is operational leverage, not accounting magic. OPM followed suit to 20.6%. PAT grew 32.7% QoQ to ₹10.5 Cr, but here's the catch: depreciation spiked to ₹25.1 Cr (from ₹8.1 Cr in Q1). This is Noumed's asset base and Saicriti capex hitting the books. Profit before tax (PBT) stayed flat at ~₹9.9 Cr, so the tax impact softened the blow. Strip out the D&A drag, and organic EBIT grew cleanly.
Gross margin hero; RM cost fell 3% despite 9% revenue growth
Gross margin 47.5% (up 660 bps QoQ), OPM 20.6%. Inventory mgmt drove RM cost down. Checks out.
Supported
H1 EBITDA margin at 17.6%, beating 17% guidance
H1 EBITDA ₹66.1 Cr at 17.6% on ₹376 Cr revenue (50% of ₹750 Cr target). Yes, ahead.
Supported
PAT grew 33% QoQ; profit before tax holding steady
PAT up 32.7% QoQ to ₹10.5 Cr; PBT stable at ~₹9.9 Cr. D&A spike is capex-driven, temporary.
Supported
Unit III, Adelaide, Prathyak will drive FY28 inflection
Unit III starts Dec 2026 (81% ramp), Adelaide Jan 2027 (TGA Q2 2027), Prathyak R&D 'non-revenue model' now, Q4 FY27 start promised. Timelines intact but unmonetized.
Overstated (unquantified, unproven)
Prathyak to generate own revenue from Q4 FY27
Currently cost center, no external R&D contracts booked. Discussions ongoing but no revenue yet.
Overstated (hedged, FY28 guidance deferred)
What changed on this call
H1 EBITDA margin beat guidance (17.6% vs. 17%)
Australia OTC contracts renewed with expanded scope (AUD232M term, 3–7.5 years)
Receivables jumped to ₹250 Cr; management calls it timing-driven, expects Q3–Q4 normalization
Prathyak revenue deferred; described as 'cost center now,' no external contracts booked yet
Adelaide TGA inspection deferred to Q2 2027; Jan 2027 commissioning target maintained but regulatory risk flagged
How the market sees it
The stock trades at ₹467, down 33.76% from its all-time high of ₹705, and is below both its 20-day (₹481.7) and 50-day (₹502.18) moving averages. RSI at 43 signals neutral momentum — not oversold panic, but not bouncing. The ownership shift is the tell: FII trimmed from 5.73% to 4.03% (−170 bps), DII from 12.86% to 8.53% (−433 bps). Promoters held steady at 51.16%. This is not a capitulation sale; it's institutional skepticism on execution. The market is saying: we believe the quarter, we believe the contracts are renewed, but we don't believe Prathyak revenue will materialize on time, or that Adelaide will ramp cleanly by Q1 FY28, or that three new facilities will simultaneously execute without margin pressure.
What to watch next
1 · Q3 receivables normalization
Receivables spiked to ₹250 Cr in Q2. Management blamed end-of-quarter timing and expects export receivables <120 days and domestic generics 120–150 days to normalize by Q3–Q4. If Q3 brings them back, the excuse validates. If they stay elevated or spike again, it signals working-capital headwind and cash-flow pressure despite EBITDA margins holding.
2 · Unit III ramp update (Dec 2026 start, Q4 FY27 full ramp)
Unit III capacity increase (155M units/month, 81% rise from baseline) starts Dec 2026. By next call (Jan–Feb 2027), we'll know if export offtake (Australia/NZ focus) is absorbing the new capacity. This is the first proof that new facility capex is generating returns.
3 · Prathyak R&D revenue signal (Q4 FY27 promised)
By next call, management promised Prathyak would begin generating external R&D revenue (currently cost center, 174 molecules in portfolio). If it's still cost-center-only, or if revenue is <₹2–3 Cr run-rate, the ₹15 Cr 60% stake acquisition looks dilutive until integration shows payoff. Watch for booked contracts (not just 'discussions'), customer names, and dollar value.
The honest read
Q2 was a steady-execution quarter, not a step-change. Margins inflected via operational leverage (inventory mgmt, RM recovery), gross margin proved sustainable at 47.5%, and Australia contracts were renewed — all credible. But the next two quarters are about proving capex converts to earnings. Unit III starts Dec 2026; Adelaide commissioning is Jan 2027 with TGA Q2 2027; Prathyak R&D is promised Q4 FY27. If all three execute, FY28 upside is real — but unquantified. Management deferred FY28 guidance to next call, and that caution is echoed by institutional trimming.
The number to track from here is organic EBIT (EBITDA margin or PBT ex-D&A), not reported PAT. Reported profit will stay depressed by capex D&A through FY27–FY28; only when new facilities start contributing in volumes (Q4 FY27 onward) will organic growth show through to net earnings. H1 EBITDA margin at 17.6% (vs. 17% guidance) is the real signal. Hold if you trust the capex story and Australia's locked-in 76% export base. Trim if Q3 receivables stay elevated or Unit III ramp shows slower-than-expected offtake.
Sai has delivered a credible H1 — margins beat guidance, gross margin expanded, Australia locked in for 7+ years. But it's not a home run yet. The FY28 inflection thesis depends on three new facilities ramping simultaneously, with Prathyak revenue still unmonetized and Adelaide regulatory risk flagged (TGA Q2 2027). The market's caution is justified until capex proves profitable. Next call (Jan–Feb 2027) will reveal whether Unit III capacity is being absorbed or warehoused, and whether Prathyak has booked external R&D contracts or is still cost-center-only. Until then, this is a hold for believers in the long-term capex thesis and a watch-and-wait for skeptics.
Informational and educational content only. Not investment advice.